Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|13|7|911-922

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.13, Iss.7, 2012-09, pp. : 911-922

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer

By Keating Gillian M.  

Drugs, Vol. 72, Iss. 3, 2012-02 ,pp. : 353-360

Adis International

Access to resources Recommend Favorite

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S.   Perry Caroline M.  

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio   Mottolese Marcella   Fabi Alessandra  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer

By Murthy Rashmi K.   Varma Ankur   Mishra Priyankana   Hess Kenneth R.   Young Elliana   Murray James L.   Koenig Kimberly H.   Moulder Stacy L.   Melhem-Bertrandt Amal   Giordano Sharon H.   Booser Daniel   Valero Vicente   Hortobagyi Gabriel N.   Esteva Francisco J.  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1932-1938

Blackwell Publishing

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite